Ridinilazole ( SMT19969 )

产品货号. M22106 CAS No. 308362-25-6

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

拼团产品询价大包装询价加入购物车

产品名称

Ridinilazole
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Ridinilazole is a novel narrow-spectrum nonabsorbable antibiotic.
产品描述

Ridinilazole is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90?=?8 mg/L) or vancomycin (MIC90?=?2 mg/L).ridinilazole , a novel antibacterial currently under development for the treatment of CDI.?Owing to its highly targeted spectrum of activity and ability to spare the normal gut microbiota, ridinilazole provides significant advantages over metronidazole and vancomycin, the mainstay antibiotics for CDI.?Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect.?Furthermore, treatment with ridinilazole results in decreased toxin production.
同义词

SMT19969
通路

GPCR/G Protein
靶点

Antibacterial
受体

Antibacterial
研究领域

Immune system
适应症

Clostridium Difficile Infection

1.Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43.

计算器

产品手册

关联产品

Vancomycin

An antibiotic used to treat a number of bacterial infections that acts by inhibiting proper cell wall synthesis.
HMPC

HMPC is a novel bacteriostatic agent that shows bacteriostatic activity against S. aureus (MIC=4μg/ml) and rescues Caenorhabditis elegans from S. aureus infection.
Methyl α-D-mannopyra...

Methyl α-D-mannopyranoside can be used as an intermediate for chemical sythesis and can ?target macrophages in anti-tuberculosis inhalation therapy.